Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy. One month after the last rituximab administration a...

Descripción completa

Detalles Bibliográficos
Autores principales: Klink, D. T., van Elburg, R. M., Schreurs, M. W. J., van Well, G. T. J.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438602/
https://www.ncbi.nlm.nih.gov/pubmed/18596903
http://dx.doi.org/10.1155/2008/271363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438602/
https://www.ncbi.nlm.nih.gov/pubmed/18596903
http://dx.doi.org/10.1155/2008/271363

Ejemplares similares